Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by OldRedon Jan 04, 2011 11:14am
90 Views
Post# 17922013

RE: Lots of possibilities

RE: Lots of possibilities

Development Pipeline

Sirona Biochem specializes in the development of carbohydrate-based molecules. Our award-winning synthetic chemists have developed a proprietary chemistry technique with an aim to improve these typically finicky molecules.  While carbohydrate-based molecules offer immense commercial potential, our efforts are focused around three programs – diabetes and obesity therapeutics, anti-aging cosmetic ingredients and biological ingredients.

Diabetes and Obesity Therapeutics - SGLT2-inhibitors (Sodium-Dependent Glucose Transporters)

Sirona Biochem is developing SGLT2 inhibitors for Type 2 diabetes and obesity. SGLT inhibitors are a potential new class of drugs for diabetes and obesity. They work differently from traditional Type 2 diabetes therapeutics which increase insulin production in the pancreas. In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by excreting excess glucose into the urine.

The kidneys filter approximately 180 gm of glucose per day from the blood which is then mostly reabsorbed back into the blood. SGLT Inhibitors inhibit the glucose reabsorption process, such that excess glucose is excreted in the urine, rather than reabsorbed into the bloodstream. That is to say, they have a hypoglycemic effect. This is a new promising potential treatment for Type 2 diabetes and obesity. 

Sirona Biochem is conducting preclinical tests on an SGLT2 inhibitor for diabetes and obesity. While there is no SGLT2 inhibitor currently on the market, the most advanced drug candidate of its kind is in Phase 3 clinical trials. Sirona Biochem aims to develop an improved, best-in-class product.

Cosmeceuticals - Anti-aging ingredients

Sirona Biochem is applying its chemistry methods to develop anti-aging cosmetic ingredients.  We believe our carbohydrate-based molecules may be able to maintain the viability of adult skin fibroblasts by protecting the fibroblasts from oxidative stress and UV radiation.

Biological ingredients

Sirona Biochem believes that there is a large market potential for the development of carbohydrate-based molecules for biological manufacturing.  Our goal is to apply our chemistry expertise towards the development of chemicals for laboratory production.  We plan to develop a natural antifreeze to preserve cells and organs.  We feel this technology can be used in laboratory solutions, organ transplantation and for the preservation of stem/islet cells.  This could be valuable in the production of insulin, human growth hormone, vaccines, interferon (anti-viral/bacterial/parasitic/tumour) and interleukin-2 (immune).

Bullboard Posts